Veeva Vault CRM Emerges as Leader in Life Sciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy VEEV?
Source: PRnewswire
- Customer Base Expansion: Veeva Vault CRM has attracted over 125 customers, including several top 20 biopharma companies, demonstrating its strong appeal and market demand in the life sciences sector, thereby solidifying its market leadership.
- Accelerated Industry Transformation: With the launch of Veeva AI, Vault CRM is accelerating the biopharma industry's shift to agent-based customer relationship management, enhancing customer engagement and operational efficiency, indicating the future direction of the industry.
- Support End Date Adjustment: Veeva has moved the end of support for Veeva CRM from September 2030 to December 2029, reflecting the success of Vault CRM and the rapid adoption of the new system by customers, ensuring a smooth transition to the new platform.
- Comprehensive Solution Offering: Vault CRM is part of a comprehensive suite of applications that support biopharma companies in managing product lifecycle and complex customer relationships, enhancing the company's competitiveness and service capabilities in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 185.910
Low
222.00
Averages
317.10
High
380.00
Current: 185.910
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data, and business consulting and is designed to meet the needs of its customers and the strategic business functions from research and development (R&D) through commercialization. Its four product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud, and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes, and partners across content management, training, quality management, assurance, and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. Veeva Data Cloud is a data platform comprised of connected reference data, deep data, and transaction data.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Carillon Eagle Fund Q4 2025 Investor Letter Highlights
- Mixed Midcap Performance: In Q4 2025, midcap stocks showed mixed results, with the Russell Midcap Growth Index declining by 3.70% while the Russell Midcap Value Index rose by 1.41%, indicating varying investor responses to different styles that could influence asset allocation decisions.
- Sector Return Disparities: Within the growth index, the materials sector led with a 17.51% absolute return, yet its limited weight in the index restricted its overall contribution, highlighting the importance of sector selection in investment strategies.
- Veeva Systems' Market Position: Veeva Systems Inc. (NYSE:VEEV) was highlighted in the investor letter despite a 15.47% decline over the past 52 weeks; the company is addressing competitive pressures by launching AI products, showcasing its deep expertise in life sciences and potential for market share recovery.
- Future Market Outlook: Carillon Eagle Fund expresses optimism for equity markets in 2026, identifying potential opportunities in Cyclicals, Healthcare, Information Technology, Financials, and Consumer Spending sectors, which may provide new growth avenues for investors.
See More
Veeva Systems Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Veeva Systems is set to release its Q4 fiscal year 2024 earnings on March 4 after market close, with consensus EPS estimates at $1.94, reflecting an 11.5% year-over-year growth, indicating the company's ongoing growth potential in the biopharmaceutical sector.
- Revenue Expectations: The anticipated revenue for Q4 is $810.95 million, representing a 12.5% year-over-year increase, which suggests strong performance in customer demand and market share, potentially solidifying its leadership position in the industry.
- Performance Beat Record: Over the past two years, Veeva has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing a consistent performance that enhances investor confidence and may positively impact stock prices.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates have experienced four upward revisions and one downward, indicating a market optimism regarding Veeva's future performance that could attract more investor interest.
See More
Veeva Vault CRM Emerges as Leader in Life Sciences
- Customer Base Expansion: Veeva Vault CRM has attracted over 125 customers, including several top 20 biopharma companies, demonstrating its strong appeal and market demand in the life sciences sector, thereby solidifying its market leadership.
- Accelerated Industry Transformation: With the launch of Veeva AI, Vault CRM is accelerating the biopharma industry's shift to agent-based customer relationship management, enhancing customer engagement and operational efficiency, indicating the future direction of the industry.
- Support End Date Adjustment: Veeva has moved the end of support for Veeva CRM from September 2030 to December 2029, reflecting the success of Vault CRM and the rapid adoption of the new system by customers, ensuring a smooth transition to the new platform.
- Comprehensive Solution Offering: Vault CRM is part of a comprehensive suite of applications that support biopharma companies in managing product lifecycle and complex customer relationships, enhancing the company's competitiveness and service capabilities in the market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Analysis & Outlook: A Reality Assessment
- Market Reaction: Stocks opened significantly lower, indicating a shift away from the previous "ignore geopolitics" mindset.
- Recovery Trend: By late morning, there was a noticeable recovery in stock prices, suggesting some stabilization in the market.
See More
Investment Potential of Eli Lilly and Veeva Systems
- Eli Lilly's Growth Momentum: Eli Lilly has demonstrated revenue growth rates exceeding mid-double digits in recent quarters, significantly outperforming large pharmaceutical companies, showcasing its leadership in the anti-obesity drug market, with new drug launches expected to further solidify its market share.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, with the anticipated launch of the oral GLP-1 drug forglipron this year and additional approvals expected in the coming years, enhancing the diversity of its product pipeline.
- Veeva Systems' Market Opportunity: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, with a goal to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, reflecting its strong competitive position in a rapidly growing market.
- Growth Potential in Cloud Market: Veeva Systems estimates an addressable market of $20 billion, significantly higher than its trailing 12-month revenue of $3.1 billion, indicating substantial growth opportunities ahead, prompting investors to consider buying at current low levels.
See More
Carillon Eagle Fund Q4 2025 Investor Letter Highlights
- Mixed Midcap Performance: In Q4 2025, midcap stocks showed mixed results, with the Russell Midcap Growth Index declining by 3.70% while the Russell Midcap Value Index rose by 1.41%, indicating varying investor responses to different styles that could influence asset allocation decisions.
- Sector Return Disparities: Within the growth index, the materials sector led with a 17.51% absolute return, yet its limited weight in the index restricted its overall contribution, highlighting the importance of sector selection in investment strategies.
- Veeva Systems' Market Position: Veeva Systems Inc. (NYSE:VEEV) was highlighted in the investor letter despite a 15.47% decline over the past 52 weeks; the company is addressing competitive pressures by launching AI products, showcasing its deep expertise in life sciences and potential for market share recovery.
- Future Market Outlook: Carillon Eagle Fund expresses optimism for equity markets in 2026, identifying potential opportunities in Cyclicals, Healthcare, Information Technology, Financials, and Consumer Spending sectors, which may provide new growth avenues for investors.
See More
Veeva Systems Set to Announce Q4 Earnings on March 4
- Earnings Announcement: Veeva Systems is set to release its Q4 fiscal year 2024 earnings on March 4 after market close, with consensus EPS estimates at $1.94, reflecting an 11.5% year-over-year growth, indicating the company's ongoing growth potential in the biopharmaceutical sector.
- Revenue Expectations: The anticipated revenue for Q4 is $810.95 million, representing a 12.5% year-over-year increase, which suggests strong performance in customer demand and market share, potentially solidifying its leadership position in the industry.
- Performance Beat Record: Over the past two years, Veeva has beaten EPS estimates 88% of the time and revenue estimates 100% of the time, showcasing a consistent performance that enhances investor confidence and may positively impact stock prices.
- Estimate Revision Trends: In the last three months, EPS estimates have seen two upward revisions and no downward adjustments, while revenue estimates have experienced four upward revisions and one downward, indicating a market optimism regarding Veeva's future performance that could attract more investor interest.
See More
Veeva Vault CRM Emerges as Leader in Life Sciences
- Customer Base Expansion: Veeva Vault CRM has attracted over 125 customers, including several top 20 biopharma companies, demonstrating its strong appeal and market demand in the life sciences sector, thereby solidifying its market leadership.
- Accelerated Industry Transformation: With the launch of Veeva AI, Vault CRM is accelerating the biopharma industry's shift to agent-based customer relationship management, enhancing customer engagement and operational efficiency, indicating the future direction of the industry.
- Support End Date Adjustment: Veeva has moved the end of support for Veeva CRM from September 2030 to December 2029, reflecting the success of Vault CRM and the rapid adoption of the new system by customers, ensuring a smooth transition to the new platform.
- Comprehensive Solution Offering: Vault CRM is part of a comprehensive suite of applications that support biopharma companies in managing product lifecycle and complex customer relationships, enhancing the company's competitiveness and service capabilities in the market.
See More
Movers: Moderna, CrowdStrike, GitLab, Coinbase, Strategy, Broadcom, and Others
- Stock Market Movement: Stock futures were showing slight increases on Wednesday.
- Investor Sentiment: Investors are assessing the potential for the U.S.-Iran conflict to escalate into a prolonged war.
See More
Analysis & Outlook: A Reality Assessment
- Market Reaction: Stocks opened significantly lower, indicating a shift away from the previous "ignore geopolitics" mindset.
- Recovery Trend: By late morning, there was a noticeable recovery in stock prices, suggesting some stabilization in the market.
See More
Investment Potential of Eli Lilly and Veeva Systems
- Eli Lilly's Growth Momentum: Eli Lilly has demonstrated revenue growth rates exceeding mid-double digits in recent quarters, significantly outperforming large pharmaceutical companies, showcasing its leadership in the anti-obesity drug market, with new drug launches expected to further solidify its market share.
- Leader in Anti-Obesity Market: Eli Lilly's tirzepatide became the world's best-selling drug last year, with the anticipated launch of the oral GLP-1 drug forglipron this year and additional approvals expected in the coming years, enhancing the diversity of its product pipeline.
- Veeva Systems' Market Opportunity: Veeva Systems provides cloud solutions to life science companies, boasting over 1,500 customers, with a goal to double its annual revenue by 2030, indicating a compound annual growth rate of nearly 18%, reflecting its strong competitive position in a rapidly growing market.
- Growth Potential in Cloud Market: Veeva Systems estimates an addressable market of $20 billion, significantly higher than its trailing 12-month revenue of $3.1 billion, indicating substantial growth opportunities ahead, prompting investors to consider buying at current low levels.
See More
